An FDA advisory committee voted 8-6 with one abstention on Thursday to recommend that BPC-157 and KPV be added to the 503A Bulks List, the roster of raw substances that compounding pharmacies may legally use to make medications for individual patients. The committee broke with the agency's own scientific staff, who had recommended against all seven peptides under review.

Most coverage is framing this as a fight about whether these peptides are safe and effective. There is a more fundamental problem in the record, raised by FDA staff during the meeting, and it sits upstream of that question.

The name does not reliably identify a molecule

An FDA staffer told the committee that the agency had encountered many substances all being marketed as "BPC-157" that had different active molecules, and put the consequence plainly: inconsistent naming conventions mean there is no basis for an expectation that the common name will always identify the same bulk drug substance.

Read that carefully, because it changes what the vote was about. Adding a substance to the bulks list is a decision about a name. If that name does not consistently correspond to one chemical entity, then the list entry does not specify what a pharmacy is permitted to compound with much precision.

It also destabilizes both sides of the evidence argument. If the "BPC-157" used in a favorable animal study is not the same molecule a compounding pharmacy obtains from a supplier, the study does not transfer to the compounded product. And the adverse event reports run into the same wall from the other direction, since you cannot confidently attribute a reaction to a substance you cannot confidently identify. The agency acknowledged as much about the three FAERS reports it received, noting its ability to interpret them was limited by missing information and confounding factors including concurrent use of other compounded products.

This is why characterization is the first of the four factors the committee is supposed to weigh, before safety, effectiveness, or history of use. It is not a formality. It is the precondition that makes the other three answerable.

The disagreement is about who carries the burden

The substantive split on the panel was captured in a single sentence of reporting from the meeting: opponents argued there was not enough data to prove safety and efficacy, and supporters essentially argued there was not enough to disprove these claims either.

That is a disagreement about the default, not about the facts, and it is worth naming precisely because it has a history. American drug regulation shifted decisively on this question in 1962, when Congress required manufacturers to demonstrate effectiveness before marketing rather than merely avoid demonstrated harm. The compounding pathway is not drug approval and does not carry the identical evidentiary requirements, so applying a different standard there is defensible on its own terms. But the direction of the shift is the same one that framework was built to prevent, and that is the actual philosophical content of an 8-6 vote.

The FDA staff review found the evidentiary gaps were not uniform across the seven substances. For KPV, TB-500, and MOTS-c, human clinical evidence was absent. For BPC-157 and others, available studies were small, uncontrolled, or contradictory. Absent and thin are different problems, and a panel voting them through together is applying one standard to both.

What 503A status does and does not mean

The distinction here matters in both directions and gets flattened in most accounts.

Compounding under Section 503A exists for individualized patient needs that approved drugs cannot meet, a patient who reacts to a dye in a commercial formulation, a child who needs a liquid version of a tablet. Adding a substance to the bulks list is not a finding that it is safe and effective. It is permission for a licensed pharmacist to use it as a starting material for a specific patient with a prescription.

Defenders of the vote can fairly say this is not approval and does not authorize mass marketing, and that physicians prescribing for individual patients under supervision is a different activity from selling a consumer product.

Critics can fairly respond that bulks-list status confers legitimacy and enables scale, and that the existing demand for these peptides does not look like individualized medicine. These substances are widely promoted for injury recovery, athletic performance, and body composition, which is a consumer market rather than a set of unmet individual clinical needs. Two of the peptides under review, MOTS-c and TB-500, are on the World Anti-Doping Agency's prohibited list, which is itself an indication of the use pattern driving demand.

The manufacturing risk is separate from the pharmacology

One category of concern here has nothing to do with whether these peptides work, and it deserves separating out because it would apply even if they did.

FDA staff flagged immunogenicity concerns tied to injection and nasal administration, alongside limited certificate-of-analysis data on impurities, aggregates, and endotoxin. Those are manufacturing quality questions. Protein and peptide products can aggregate, and aggregates are a recognized driver of immune reactions. Endotoxin contamination in an injectable product is dangerous independent of what the product contains. Approved injectable drugs are made under process controls specifically designed to manage these risks.

This is the category where compounding has produced the most serious harm historically. The 2012 fungal meningitis outbreak traced to contaminated compounded injections, which killed dozens of people, is the reason the current compounding oversight framework exists in its present form. Invoking it is not a prediction about peptides. It is the reason injectable compounding is regulated more tightly than a topical cream.

The panel that cast the vote

Two facts about the committee itself are relevant to how much weight the recommendation carries, and both are documented rather than inferred.

The advisory panel was recently overhauled, and many of the new members have ties to the peptide industry, which has drawn criticism about potential conflicts of interest. Separately, Health Secretary Robert F. Kennedy Jr., who oversees the FDA, has publicly endorsed easing restrictions on peptides.

Neither fact establishes that the vote was wrong on the merits, and industry expertise on an advisory panel is not inherently improper, since the people who know a field best often have relationships within it. But advisory committees derive their authority from being independent of the interests they evaluate, and a panel reconstituted shortly before a vote that goes against its own agency's scientists will face questions about that independence.

What happens next

PCAC recommendations are advisory and non-binding. The FDA makes the final decision on whether a substance joins the 503A Bulks List, and while the agency usually follows the committee, it has departed from PCAC recommendations before.

So the operative question is now whether FDA leadership sides with its own review staff, who recommended against all seven substances, or with its advisory committee, which voted for at least three. That decision will be made by an agency whose department head has publicly stated a position on the question, which is the circumstance that makes this more than a routine compounding matter.

The narrower point stands regardless of the outcome. Before anyone can settle whether these peptides help or harm, someone has to establish that the name on the vial reliably corresponds to a specific molecule. The agency's own scientists testified that it currently does not. That problem is solvable through characterization standards and testing requirements, and solving it would make every subsequent question answerable. Voting first and characterizing later reverses an order that exists for a reason.

Further reading